Shanghai Pharma's Shanghai Sine Gets NMPA Approval for Omeprazole Sodium Bicarbonate Dry Suspension
Shanghai Pharmaceuticals Holding Co. , Ltd. announced on August 3 that its subsidiary Shanghai Sine has received a Drug Registration Certificate from the National Medical Products Administration for omeprazole sodium bicarbonate dry suspension (I), granting approval for production. The medication is primarily used for the short-term treatment of active duodenal ulcer and gastroesophageal reflux disease.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 35/100 and 85% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.